Stock News

EPS for XOMA (XOMA) Expected At $-0.50; 2 Analysts Covering Atlas Financial Holdings, Inc. (AFH)

Analysts expect XOMA Corporation (NASDAQ:XOMA) to report $-0.50 EPS on March, 15.They anticipate $2.39 EPS change or 82.70% from last quarter’s $-2.89 EPS. After having $1.98 EPS previously, XOMA Corporation’s analysts see -125.25% EPS growth. The stock decreased 2.56% or $0.68 during the last trading session, reaching $25.9. About 188,698 shares traded or 3.66% up from the average. XOMA Corporation (NASDAQ:XOMA) has declined 51.66% since February 18, 2017 and is downtrending. It has underperformed by 68.36% the S&P500.

Among 3 analysts covering Atlas Financial Holdings (NASDAQ:AFH), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Atlas Financial Holdings had 5 analyst reports since September 5, 2015 according to SRatingsIntel. The rating was downgraded by TheStreet to “Hold” on Saturday, September 5. The stock of Atlas Financial Holdings, Inc. (NASDAQ:AFH) has “Hold” rating given on Tuesday, September 8 by TheStreet. The firm earned “Buy” rating on Wednesday, January 10 by Sandler O’Neill. Boenning & Scattergood maintained the shares of AFH in report on Tuesday, June 13 with “Buy” rating. See Atlas Financial Holdings, Inc. (NASDAQ:AFH) latest ratings:

10/01/2018 Broker: Sandler O’Neill Rating: Buy New Target: $24.0 Maintain

It closed at $18.45 lastly. It is down 15.27% since February 18, 2017 and is downtrending. It has underperformed by 31.97% the S&P500.

Atlas Financial Holdings, Inc., through its subsidiaries, engages in underwriting commercial automobile insurance policies in the United States. The company has market cap of $221.97 million. The companyÂ’s automobile insurance products provide insurance coverage in three primary areas, including liability, accident benefits, and physical damage. It has a 138.72 P/E ratio. It focuses on the light commercial vehicle sector, including taxi cabs, non-emergency para-transit, limousine, livery, and business autos.

Since August 22, 2017, it had 0 insider buys, and 19 sales for $1.54 million activity. Shares for $57,961 were sold by KINGSWAY AMERICA INC. $20,855 worth of Atlas Financial Holdings, Inc. (NASDAQ:AFH) was sold by Giles Bruce Wayne. Another trade for 783 shares valued at $14,924 was sold by Romano Paul Anthony JR. Shugrue Joseph Raymond sold 1,088 shares worth $20,855. On Tuesday, December 12 Wollney Scott D sold $33,546 worth of Atlas Financial Holdings, Inc. (NASDAQ:AFH) or 1,750 shares. The insider DiMaggio Leslie sold 657 shares worth $12,522.

Investors sentiment increased to 1.76 in 2017 Q3. Its up 0.20, from 1.56 in 2017Q2. It is positive, as 6 investors sold Atlas Financial Holdings, Inc. shares while 15 reduced holdings. 11 funds opened positions while 26 raised stakes. 9.03 million shares or 2.06% more from 8.85 million shares in 2017Q2 were reported. California State Teachers Retirement Systems has invested 0% in Atlas Financial Holdings, Inc. (NASDAQ:AFH). Ny State Common Retirement Fund reported 0% stake. Ranger Investment Management Limited Partnership invested 0.18% in Atlas Financial Holdings, Inc. (NASDAQ:AFH). Nationwide Fund reported 0% of its portfolio in Atlas Financial Holdings, Inc. (NASDAQ:AFH). Northern Tru holds 116,737 shares or 0% of its portfolio. Returns Mgmt Limited Co stated it has 2.65% of its portfolio in Atlas Financial Holdings, Inc. (NASDAQ:AFH). Rice Hall James And Assocs Ltd Liability Com owns 118,399 shares. Prudential Fincl has invested 0% in Atlas Financial Holdings, Inc. (NASDAQ:AFH). Invesco Ltd has invested 0% in Atlas Financial Holdings, Inc. (NASDAQ:AFH). Legal & General Grp Pcl invested in 0% or 1,637 shares. Parametric Port Associate Limited Liability Com holds 0% or 11,552 shares. The New York-based Bnp Paribas Arbitrage Sa has invested 0% in Atlas Financial Holdings, Inc. (NASDAQ:AFH). Int Grp has invested 0% in Atlas Financial Holdings, Inc. (NASDAQ:AFH). Manufacturers Life Insurance The holds 9,724 shares or 0% of its portfolio. Buckhead Mngmt Limited invested 0.28% of its portfolio in Atlas Financial Holdings, Inc. (NASDAQ:AFH).

Among 7 analysts covering Xoma Limited (NASDAQ:XOMA), 2 have Buy rating, 0 Sell and 5 Hold. Therefore 29% are positive. Xoma Limited had 22 analyst reports since July 23, 2015 according to SRatingsIntel. As per Monday, November 14, the company rating was downgraded by Wedbush. The stock of XOMA Corporation (NASDAQ:XOMA) has “Hold” rating given on Monday, August 14 by Wedbush. On Wednesday, July 22 the stock rating was downgraded by Ladenburg Thalmann to “Neutral”. The firm has “Buy” rating given on Tuesday, October 17 by H.C. Wainwright. The company was maintained on Thursday, August 10 by H.C. Wainwright. H.C. Wainwright maintained it with “Buy” rating and $38.0 target in Thursday, December 7 report. The firm has “Buy” rating by H.C. Wainwright given on Thursday, January 18. The rating was downgraded by Zacks to “Hold” on Friday, September 4. The firm has “Buy” rating by Wedbush given on Tuesday, December 19. Jefferies downgraded XOMA Corporation (NASDAQ:XOMA) on Thursday, July 23 to “Hold” rating.

XOMA Corporation discovers, develops, and commercializes antibody therapeutics in the United States, Europe, and the Asia Pacific. The company has market cap of $210.93 million. The company's product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia. It currently has negative earnings. The Company’s preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy.

Leave a Reply

Your email address will not be published. Required fields are marked *